<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03551275</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-132-1</org_study_id>
    <nct_id>NCT03551275</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
  <official_title>A Multicenter Open-Label Non-Comparative Dose Escalation Study (Phase 1) of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 (JSC BIOCAD, Russia) in Patients With Relapsing-Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BCD-132 is a humanized monoclonal antibody against CD20. BCD-132-1 is a Multicenter&#xD;
      Open-Label Non-Comparative Dose Escalation Study (Phase 1) of the Pharmacodynamics,&#xD;
      Pharmacokinetics, Safety, and Immunogenicity of BCD-132 (JSC BIOCAD, Russia) in Patients with&#xD;
      Relapsing-Remitting Multiple Sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2018</start_date>
  <completion_date type="Actual">March 28, 2019</completion_date>
  <primary_completion_date type="Actual">October 18, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients who developed AEs/SAEs that, in the Investigator's opinion, are related to BCD-132</measure>
    <time_frame>day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-132</measure>
    <time_frame>day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of patients, in each group, who discontinued the study due to AEs/SAEs</measure>
    <time_frame>day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of BAb- and NAb-positive patients</measure>
    <time_frame>day 169</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (0-2016 hours)</measure>
    <time_frame>day 85, day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-∞)</measure>
    <time_frame>day 85, day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC (0-2016 hours)</measure>
    <time_frame>day 85, day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC (0-∞)</measure>
    <time_frame>day 85, day 169</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>CUA</measure>
    <time_frame>day 169</time_frame>
    <description>Changes in MRI markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients without contrast-enhancing lesions</measure>
    <time_frame>day 169</time_frame>
    <description>Changes in MRI markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of new or enlarging T2-weighted lesions</measure>
    <time_frame>day 169</time_frame>
    <description>Changes in MRI markers over time</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients without new or enlarging T2-weighted lesions</measure>
    <time_frame>day 169</time_frame>
    <description>Changes in MRI markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in T2-weighted lesion volume</measure>
    <time_frame>day 169</time_frame>
    <description>Changes in MRI markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in hypointense T1-weighted lesion volume</measure>
    <time_frame>day 169</time_frame>
    <description>Changes in MRI markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>day 169</time_frame>
    <description>EDSS is a scale for assessing neurologic impairment in MS. It consists of eight functional systems (FS) which are used to derive the EDSS steps (score) ranging from 0 (normal) to 10 (death due to MS). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the participant's score is determined between 0 to 10. A positive change from baseline indicates improvement</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of relapse-free patients</measure>
    <time_frame>day 169</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cohort no. 1, BCD-132, 100 mg, IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort no. 1, Group #1 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 100 mg.&#xD;
Cohort no. 1, Group #2 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 50 mg and second dose of 50 mg IV after 14 days period after first infusion.&#xD;
If there is no DLT within the first 14 days after infusion then Cohort no.2 is included.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort no. 2, BCD-132, 250 mg, IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort no. 2, Group #3 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg.&#xD;
Cohort no. 2, Group #4 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 125 mg and second dose of 125 mg IV after 14 days period after first infusion.&#xD;
If there is no DLT within the first 14 days after infusion then Cohort no.3 is included.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort no. 3, BCD-132, 500 mg, IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort no. 3, Group #5 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg.&#xD;
Cohort no. 3, Group #6 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg and second dose of 250 mg IV after 14 days period after first infusion.&#xD;
If there is no DLT within the first 14 days after infusion then Cohort no.4 is included.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort no. 4, BCD-132, 1000 mg, IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort no. 4, Group #7 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 1000 mg.&#xD;
Cohort no. 4, Group #8 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg and second dose of 500 mg IV after 14 days period after first infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-132</intervention_name>
    <description>Dose Escalation Study</description>
    <arm_group_label>Cohort no. 1, BCD-132, 100 mg, IV</arm_group_label>
    <arm_group_label>Cohort no. 2, BCD-132, 250 mg, IV</arm_group_label>
    <arm_group_label>Cohort no. 3, BCD-132, 500 mg, IV</arm_group_label>
    <arm_group_label>Cohort no. 4, BCD-132, 1000 mg, IV</arm_group_label>
    <other_name>humanized monoclonal antibody against CD20</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent to participate in the study;&#xD;
&#xD;
          -  Men and women aged from 18 to 60 years (inclusive) on the day of signing informed&#xD;
             consent;&#xD;
&#xD;
          -  Confirmed diagnosis of relapsing-remitting multiple sclerosis (according to McDonald&#xD;
             criteria 2010);&#xD;
&#xD;
          -  Documentary evidence that within the last 12 months before signing informed consent&#xD;
             the patient had:&#xD;
&#xD;
               1. At least one relapse, or&#xD;
&#xD;
               2. At least one gadolinium enhancing T1-weighted lesion or one new T2-weighted&#xD;
                  lesion in dynamics.&#xD;
&#xD;
          -  The patient should be neurologically stable during 30 days before signing informed&#xD;
             consent (i.e. the patient should not have any new or aggravated neurological symptoms&#xD;
             during this period, as told by the patient; or the patient's condition should be&#xD;
             completely stabilized since the last relapse, and the duration of stabilization should&#xD;
             be at least 30 days);&#xD;
&#xD;
          -  A total EDSS score of 0 to 5.5 inclusive (assessed by the Assessing Neurologist);&#xD;
&#xD;
          -  Presence of IgG antibodies to varicella zoster virus according to screening results;&#xD;
&#xD;
          -  Patients of childbearing potential and their partners with preserved reproductive&#xD;
             function must implement reliable contraceptive methods starting from signing informed&#xD;
             consent and throughout the study. This requirement does not apply to patients after&#xD;
             operative sterilization. Reliable contraception methods include one barrier method in&#xD;
             combination with one of the following: spermicides, intrauterine device/oral&#xD;
             contraceptives.&#xD;
&#xD;
          -  Body weight ≥65 kg at the screening&#xD;
&#xD;
          -  The absence of suicidal ideation and suicidal behavior, as assessed by the C-SSRC&#xD;
             scale, for the period of the 1st month preceding the signing of the informed consent&#xD;
             by the patient (0 score in the evaluation of suicidal ideation and the lack of&#xD;
             positive responses in the section of suicidal behavior) established in the screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary and secondary progressive multiple sclerosis;&#xD;
&#xD;
          -  Multiple sclerosis duration of more than 10 years with EDSS score ≤2.0 according to&#xD;
             screening results;&#xD;
&#xD;
          -  Other conditions (except for multiple sclerosis) that can affect the assessment of&#xD;
             multiple sclerosis symptoms: to mask, aggravate, change symptoms of multiple&#xD;
             sclerosis, result in clinical signs or laboratory instrumental findings suggesting&#xD;
             multiple sclerosis;&#xD;
&#xD;
          -  A relapse during the screening period;&#xD;
&#xD;
          -  Any acute infections, relapses of chronic infections or any other chronic diseases&#xD;
             that are present on the day of signing informed consent and can, as judged by the&#xD;
             Investigator, negatively affect the patient's safety during the study treatment;&#xD;
&#xD;
          -  HIV, hepatitis B, hepatitis C, or syphilis;&#xD;
&#xD;
          -  Metabolic abnormalities (disorders) manifesting as:&#xD;
&#xD;
               1. baseline creatinine levels increased more than 2-fold vs. upper limit of normal;&#xD;
&#xD;
               2. baseline urea levels increased more than 3-fold vs. upper limit of normal;&#xD;
&#xD;
               3. baseline ALT, AST or GGT levels increased more than 2.5-fold vs. upper limit of&#xD;
                  normal;&#xD;
&#xD;
               4. baseline bilirubin levels increased more than 1.5-fold vs. upper limit of normal;&#xD;
&#xD;
          -  Baseline leukocyte counts lower than &lt;3.0 × 10 9/L, platelet counts lower than &lt;125 ×&#xD;
             10 9/L or hemoglobin levels &lt;100 g/L;&#xD;
&#xD;
          -  A history of severe depression, suicidal thoughts or suicide attempts;&#xD;
&#xD;
          -  Signs of clinical significant depression (baseline Beck's score of more than 15);&#xD;
&#xD;
          -  A history of hypothyroidism/hyperthyroidism and/or baseline abnormalities of TSH&#xD;
             levels vs. lower or upper limits of normal;&#xD;
&#xD;
          -  Epilepsy;&#xD;
&#xD;
          -  Pregnancy, lactation or planned pregnancy over the entire study period;&#xD;
&#xD;
          -  A history of use&#xD;
&#xD;
               1. any time before signing informed consent: anti-B-cell agents (e.g., rituximab,&#xD;
                  ocrelizumab, abatacept, belimumab, ofatumumab, etc.);&#xD;
&#xD;
               2. any time before signing informed consent: alemtuzumab, anti-CD4 agents,&#xD;
                  daclizumab, teriflunomide, laquinimod, mitoxantrone, cladribine, total lymphatic&#xD;
                  irradiation, bone marrow transplant;&#xD;
&#xD;
               3. within 2 years (24 months) before signing informed consent: cyclophosphamide,&#xD;
                  cyclosporin, azathioprine; mycophenolate mofetil, fingolimod and other&#xD;
                  sphingosine-1-phosphate (S1P) receptor-modulating agents, natalizumab ;&#xD;
&#xD;
               4. therapy with immunoglobulin drug products within 12 weeks before signing informed&#xD;
                  consent.&#xD;
&#xD;
          -  Systemic corticosteroids used within 30 days before signing informed consent;&#xD;
&#xD;
          -  Hypersensitivity to any of BCD-132 ingredients;&#xD;
&#xD;
          -  Known alcoholic or drug dependency or signs of present alcoholic/drug dependence that,&#xD;
             in the Investigator's opinion, can be contraindications for study therapy of multiple&#xD;
             sclerosis with anti-CD20 monoclonal antibodies or limit treatment compliance;&#xD;
&#xD;
          -  Inability to follow the Protocol procedures (in the Investigator's opinion);&#xD;
&#xD;
          -  Contraindications to MRI or use of gadolinium-containing contrast agents:&#xD;
&#xD;
               1. Metal foreign objects in the body, magnetic implants, ferromagnetic clips for&#xD;
                  cerebral vessels, artificial heart valves, electronic middle ear implants,&#xD;
                  pacemakers;&#xD;
&#xD;
               2. A history of allergy to gadolinium or gadolinium-containing contrast agents;&#xD;
&#xD;
             с) Fear of cramped spaces; d) Kidney function impairment with a risk of delayed&#xD;
             gadolinium elimination (creatinine level increased to more than 2 x upper limit of&#xD;
             normal); e) Documented diagnosis of sickle cell or hemolytic anemia, hemoglobinopathy.&#xD;
&#xD;
          -  Any malignancies or a history of malignancies, except for cured basal cell carcinoma&#xD;
             or cervical cancer in situ;&#xD;
&#xD;
          -  Vaccination within 6 weeks before signing informed consent (as told by the patient);&#xD;
&#xD;
          -  Participation in other clinical studies within 90 days before signing informed&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City Hospital #15</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Regional Research and Clinical Institute</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Center of Neurology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of the Human Brain n. a. N.P. Bekhtereva Russian Academy of Sciences</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>May 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCD-132</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>anti-CD20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

